Patent Application Titled "Oral Delayed Burst Formulation Of Low-Dose Naltrexone And Methods For Treating Fibromyalgia And Long Covid" Published Online (USPTO 20230372328).

Předmět:	POST-acute COVID-19 syndrome PATENT applications SARS-CoV-2 NALTREXONE FIBROMYALGIA
Zdroj:	Medical Letter on the CDC & FDA; 12/17/2023, p3760-3760, 1p
Abstrakt:	A patent application has been published online for an oral delayed burst formulation of low-dose naltrexone (LDN) that aims to treat fibromyalgia and Long Covid. The application highlights the need for a LDN formulation that avoids the side effects of opioid antagonists and discusses the symptoms and challenges associated with these conditions. The proposed formulation consists of a core containing naltrexone and other excipients, a delayed release layer, and a subcoat layer. It is designed to be taken shortly before sleep. The patent application provides detailed information on the composition and administration methods of the formulation. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu